Literature DB >> 32487493

Metabolomics profiling of tobacco exposure in children with cystic fibrosis.

Benjamin L Wisniewski1, Chandra L Shrestha2, Shuzhong Zhang2, Rohan Thompson3, Myron Gross4, Judith A Groner5, Karan Uppal6, Octavio Ramilo7, Asuncion Mejias7, Benjamin T Kopp8.   

Abstract

BACKGROUND: Inflammation is integral to early disease progression in children with CF. The effect of modifiable environmental factors on infection and inflammation in persons with CF is poorly understood. Our prior studies determined that secondhand smoke exposure (SHSe) is highly prevalent in young children with CF. SHSe is associated with increased inflammation, heightened bacterial burden, and worsened clinical outcomes. However, the specific metabolite and signaling pathways that regulate responses to SHSe in CF are relatively unknown.
METHODS: High-resolution metabolomics was performed on plasma samples from infants (n = 25) and children (n = 40) with CF compared to non-CF controls (n = 15). CF groups were stratified according to infant or child age and SHSe status.
RESULTS: Global metabolomic profiles segregated by age and SHSe status. SHSe in CF was associated with changes in pathways related to steroid biosynthesis, fatty acid metabolism, cysteine metabolism, and oxidative stress. CF infants with SHSe demonstrated enrichment for altered metabolite localization to the small intestine, liver, and striatum. CF children with SHSe demonstrated metabolite enrichment for organs/tissues associated with oxidative stress including mitochondria, peroxisomes, and the endoplasmic reticulum. In a confirmatory analysis, SHSe was associated with changes in biomarkers of oxidative stress and cellular adhesion including MMP-9, MPO, and ICAM-1.
CONCLUSIONS: SHSe in young children and infants with CF is associated with altered global metabolomics profiles and specific biochemical pathways, including enhanced oxidative stress. SHSe remains an important but understudied modifiable variable in early CF disease.
Copyright © 2020 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cystic fibrosis; Metabolites; Tobacco

Mesh:

Substances:

Year:  2020        PMID: 32487493      PMCID: PMC7492400          DOI: 10.1016/j.jcf.2020.05.003

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  52 in total

1.  Passive smoking in cystic fibrosis.

Authors:  H Gilljam; C Stenlund; A Ericsson-Hollsing; B Strandvik
Journal:  Respir Med       Date:  1990-07       Impact factor: 3.415

Review 2.  Graph-based methods for analysing networks in cell biology.

Authors:  Tero Aittokallio; Benno Schwikowski
Journal:  Brief Bioinform       Date:  2006-07-30       Impact factor: 11.622

3.  Age and environmental exposures influence the fecal bacteriome of young children with cystic fibrosis.

Authors:  Brett R Loman; Chandra L Shrestha; Rohan Thompson; Judith A Groner; Asuncion Mejias; Kathryn L Ruoff; George A O'Toole; Michael T Bailey; Benjamin T Kopp
Journal:  Pediatr Pulmonol       Date:  2020-04-10

4.  Metabolomic responses to lumacaftor/ivacaftor in cystic fibrosis.

Authors:  Benjamin T Kopp; Scott McCulloch; Chandra L Shrestha; Shuzhong Zhang; Lisa Sarzynski; Frederick W Woodley; Don Hayes
Journal:  Pediatr Pulmonol       Date:  2018-02-20

5.  Metabolomic biomarkers predictive of early structural lung disease in cystic fibrosis.

Authors:  Charles R Esther; Lidija Turkovic; Tim Rosenow; Marianne S Muhlebach; Richard C Boucher; Sarath Ranganathan; Stephen M Stick
Journal:  Eur Respir J       Date:  2016-11-11       Impact factor: 16.671

6.  Metabolomic analysis of bronchoalveolar lavage fluid from cystic fibrosis patients.

Authors:  Justyna E Wolak; Charles R Esther; Thomas M O'Connell
Journal:  Biomarkers       Date:  2009-02       Impact factor: 2.658

Review 7.  Early lung disease in cystic fibrosis.

Authors:  Hartmut Grasemann; Felix Ratjen
Journal:  Lancet Respir Med       Date:  2013-03-12       Impact factor: 30.700

8.  Interactions between secondhand smoke and genes that affect cystic fibrosis lung disease.

Authors:  J Michael Collaco; Lori Vanscoy; Lindsay Bremer; Kathryn McDougal; Scott M Blackman; Amanda Bowers; Kathleen Naughton; Jacky Jennings; Jonathan Ellen; Garry R Cutting
Journal:  JAMA       Date:  2008-01-30       Impact factor: 56.272

9.  Three-Dimensional Microbiome and Metabolome Cartography of a Diseased Human Lung.

Authors:  Neha Garg; Mingxun Wang; Embriette Hyde; Ricardo R da Silva; Alexey V Melnik; Ivan Protsyuk; Amina Bouslimani; Yan Wei Lim; Richard Wong; Greg Humphrey; Gail Ackermann; Timothy Spivey; Sharon S Brouha; Nuno Bandeira; Grace Y Lin; Forest Rohwer; Douglas J Conrad; Theodore Alexandrov; Rob Knight; Pieter C Dorrestein
Journal:  Cell Host Microbe       Date:  2017-10-19       Impact factor: 21.023

10.  Metabolomic assessment of exposure to near-highway ultrafine particles.

Authors:  Douglas I Walker; Kevin J Lane; Ken Liu; Karan Uppal; Allison P Patton; John L Durant; Dean P Jones; Doug Brugge; Kurt D Pennell
Journal:  J Expo Sci Environ Epidemiol       Date:  2018-12-05       Impact factor: 5.563

View more
  1 in total

1.  Sweat metabolomics before and after intravenous antibiotics for pulmonary exacerbation in people with cystic fibrosis.

Authors:  Frederick W Woodley; Emrah Gecili; Rhonda D Szczesniak; Chandra L Shrestha; Christopher J Nemastil; Benjamin T Kopp; Don Hayes
Journal:  Respir Med       Date:  2021-11-23       Impact factor: 3.415

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.